Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009

Clinical Infectious Diseases

Volumn 57, Issue 8, 2013, Pages 1081-1093

  Kurbatova, Ekaterina V ^a   Cavanaugh, Joseph S ^a   Dalton, Tracy ^a   Click, Eleanor S ^a   Cegielski, J Peter ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

drug resistance; epidemiology; pyrazinamide; tuberculosis

Indexed keywords

PYRAZINAMIDE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIAN; BACTERIUM CULTURE; CHILD; DRUG RESISTANT TUBERCULOSIS; ETHNICITY; FEMALE; GENOTYPE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTOR VARIABLE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREND STUDY; TUBERCULOSIS; UNITED STATES;

DRUG RESISTANCE; EPIDEMIOLOGY; PYRAZINAMIDE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES; YOUNG ADULT;

EID: 84884925227     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit452     Document Type: Article

References (42)

1. Francis J. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed, San Francisco: Curry National Tuberculosis Center and California Department of Public Health, 2008.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, Switzerland: WHO, 2011.
3. The US Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52:1-77.
4. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7:6-21. (Pubitemid 36427026)
5. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796-806.
6. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982; 126:460-2.
7. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. The results up to 30 months. Tubercle 1981; 62:95-102.
8. Tasneen R, Li S-Y, Peloquin C, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55:5485-92.
9. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-20.
10. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
11. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70:748-54.
12. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51:42-9. (Pubitemid 34060132)
13. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actimomycets; approved standard. NCCLS document M24-A Wayne, PA: NCCLS, 2003.
14. NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actimomycets; approved standard. NCCLS document M24-A2 Wayne, PA: NCCLS, 2011.
15. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2010; 48:300-1.
16. Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967; 95:461-9.
17. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2:662-7. (Pubitemid 26191953)
18. Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 2008; 47:168-75. (Pubitemid 351920616)
19. LoBue PA, Enarson DA, Thoen CO. Tuberculosis in humans and animals: an overview. Int J Tuberc Lung Dis 2010; 14:1075-8.
20. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2010. Atlanta, GA: CDC, 2011.
21. US Centers for Disease Control and Prevention. Report of verified case of tuberculosis (rvct) instruction manual. Available at: http://ftp. cdc.gov/pub/software/tims/2009%20rvct%20documentation/rvct%20 training%20materials/rvct%20instruction%20manual.pdf. Accessed 10 July 2013.
22. US Centers for Disease Control and Prevention. Tuberculosis laboratory aggregate report. Available at: http://www.cdc.gov/tb/publications/ reportsarticles/2009aggregatereport.pdf. Accessed 10 July 2013.
23. National TB Controllers Association/CDC Advisory Group on Tuberculosis Genotyping. Guide to the application of genotyping to tuberculosis prevention and control. Atlanta, GA: CDC, 2004.
24. Click ES, Moonan PK,Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012; 54:211-9.
25. Centers for Disease Control and Prevention. Tuberculosis genotyping- United States, 2004-2010. MMWR Morb Mortal Wkly Rep 2012; 61:723-5.
26. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19:335-51. (Pubitemid 30070608)
27. Lumb R, Bastion I, Carter R, Jelfs P, Keehner T, Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell 2011; 35:154-61.
28. Bai GH, Park YK, Choi YW, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007; 11:571-6.
29. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 2010; 10:223.
30. Pierre-Audigier C, Surcouf C, Cadet-Daniel V, et al. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16:221-3, i-ii.
31. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46:3459-64.
32. Kim HJ, Kwak HK, Lee J, et al. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int J Tuberc Lung Dis 2012; 16:98-103.
33. Chiu YC, Huang SF, Yu KW, Lee YC, Feng JY, Su WJ. Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect Dis 2011; 11:240.
34. Chan RC, Hui M, Chan EW, et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59:866-73. (Pubitemid 47078721)
35. de Jong BC, Onipede A, Pym AS, et al. Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol 2005; 43:3530-2. (Pubitemid 40981386)
36. Hannan MM, Desmond EP, Morlock GP, Mazurek GH, Crawford JT. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 2001; 39:647-50. (Pubitemid 32150834)
37. Pareek M, Evans J, Innes J, et al. Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. Thorax 2013; 68:221-9.
38. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7:328-37. (Pubitemid 46590063)
39. Simons SO, van Ingen J, van der Laan T, et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2012; 50:428-34.
40. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol 2012; 50: 1233-9.
41. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032-41.
42. Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F. A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2006; 58:327-31. (Pubitemid 44294943)